Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast media presented as a strength/form for intravenous use. It enhances the visibility of vascular structures and organs during diagnostic imaging procedures in adult and pediatric patients. GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Optiray is an iodinated contrast agent used in radiographic procedures that require enhanced visualization of internal anatomy.

- Computed Tomography (CT) scanning: improves delineation of vascular and soft‑tissue structures. - Angiography: highlights blood vessels to aid in diagnosis and interventional planning. - Intravenous urography: enhances urinary tract imaging for better detection of obstructions. - Myelography: provides contrast for spinal canal evaluation. - Cardiac CT: assists in coronary artery assessment. - Pediatric imaging: offers safe contrast enhancement for children undergoing diagnostic scans.

Adverse reactions to Optiray are generally related to its iodine content and route of administration.

Common Side Effects: - Warm sensation or flushing at the injection site. - Nausea or mild vomiting. - Headache. - Transient metallic taste. - Mild itching or urticaria.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Acute kidney injury, particularly in patients with pre‑existing renal impairment. - Hypotension or cardiovascular collapse. - Pulmonary edema. - Seizures. - Persistent skin rash or Stevens‑Johnson syndrome.

Optiray should be used with careful clinical assessment and monitoring.

- Renal function assessment: evaluate baseline kidney function before administration. - Allergy history: screen for prior reactions to iodinated contrast agents. - Hydration status: ensure adequate patient hydration to reduce renal risk. - Cardiovascular status: monitor patients with heart failure or unstable hemodynamics. - Concomitant nephrotoxic drugs: avoid or adjust dosing of other renal‑impacting medications. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Optiray may interact with several medications that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - Metformin: increased risk of lactic‑acidosis when renal function declines after contrast exposure. - NSAIDs: combined nephrotoxic potential may exacerbate kidney injury.

Moderate Interactions (Monitor Closely): - ACE inhibitors/ARBs: may potentiate contrast‑induced nephropathy; monitor renal parameters. - Diuretics: can affect fluid balance and renal clearance; adjust hydration as needed. - Beta‑blockers: may mask early signs of anaphylaxis; observe closely. - Thyroid hormones: iodine load can alter thyroid function tests; check levels if clinically indicated. - Radiopharmaceuticals: overlapping imaging agents may affect diagnostic interpretation.